公开(公告)号：US10961229B2

公开(公告)日：2021-03-30

申请号：US16502684

申请日：2019-07-03

Applicant: Bristol-Myers Squibb Company

Inventor： Imadul Islam ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Srinivas Cheruku ,  Poornima Shetty ,  Grandhi Venkat Ram Krishna Mohan Gupta ,  John E. Macor

IPC: C07D403/14 ,  C07D401/12 ,  C07D471/08 ,  A61P25/28 ,  A61P25/02 ,  A61P25/24 ,  A61P25/16 ,  C07D401/14 ,  C07D487/08

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US20180312495A1

公开(公告)日：2018-11-01

申请号：US15767385

申请日：2016-10-13

Applicant: Bristol-Myers Squibb Company

Inventor： Imadul Islam ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Srinivas Cheruku ,  Poornima Shetty ,  John E. Macor

IPC: C07D413/04 ,  A61P25/24 ,  C07D413/14 ,  C07D413/12

CPC classification number: C07D413/04 ,  C07D413/14

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMD A) receptor and thereby making them useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US20200071304A1

公开(公告)日：2020-03-05

申请号：US16502684

申请日：2019-07-03

Applicant: Bristol-Myers Squibb Company

Inventor： Imadul Islam ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Srinivas Cheruku ,  Poornima Shetty ,  Grandhi Venkat Ram Krishna Mohan Gupta ,  John E. Macor

IPC: C07D403/14 ,  C07D401/12 ,  C07D471/08 ,  A61P25/28 ,  A61P25/02 ,  A61P25/24 ,  A61P25/16 ,  C07D401/14 ,  C07D487/08

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US10344020B2

公开(公告)日：2019-07-09

申请号：US15767386

申请日：2016-10-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Imadul Islam ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Srinivas Cheruku ,  Poornima Shetty ,  Grandhi Venkat Ram Krishna Mohan Gupta ,  John E. Macor

IPC: C07D403/14 ,  C07D401/12 ,  C07D471/08 ,  A61P25/28 ,  A61P25/02 ,  A61P25/24 ,  A61P25/16 ,  C07D401/14 ,  C07D487/08

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US10954225B2

公开(公告)日：2021-03-23

申请号：US16707382

申请日：2019-12-09

Applicant: Bristol-Myers Squibb Company

Inventor： Imadul Islam ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Srinivas Cheruku ,  Poornima Shetty ,  John E. Macor

IPC: C07D413/14 ,  C07D413/04 ,  A61K31/497 ,  A61K31/4523 ,  A61P25/24 ,  C07D413/12

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMDA) receptor and thereby making them useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US20180312491A1

公开(公告)日：2018-11-01

申请号：US15767386

申请日：2016-10-13

Applicant: Bristol-Myers Squibb Company

Inventor： Imadul Islam ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Srinivas Cheruku ,  Poornima Shetty ,  Grandhi Venkat Ram Krishna Mohan Gupta ,  John E. Macor

IPC: C07D403/14 ,  C07D401/14 ,  C07D487/08 ,  A61P25/24 ,  A61P25/28 ,  A61P25/02 ,  A61P25/16

CPC classification number: C07D403/14 ,  A61P25/02 ,  A61P25/16 ,  A61P25/24 ,  A61P25/28 ,  C07D401/12 ,  C07D401/14 ,  C07D471/08 ,  C07D487/08

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.